Somatoform Disorders

W. Curt LaFrance

doi:10.1055/s-0029-1223875

Seminars in Neurology, Table of Contents

Semin Neurol 2009; 29(3): 234-246
DOI: 10.1055/s-0029-1223875

Somatoform Disorders

W. Curt LaFrance¹

¹Division of Neuropsychiatry and Behavioral Neurology, Brown Medical School/Rhode Island Hospital, Providence, Rhode Island

Abstract

ABSTRACT

The fields of neurology and psychiatry were originally practiced as a unitary model. As the fields dichotomized patients into “organic” and “functional,” patients with medically unexplained symptoms fell between the borderlands. Despite their significant prevalence, somatoform disorders (SDs) are grossly under-recognized and lack effective treatments. This article reviews diagnostic criteria, differential diagnoses, examination findings, and treatments for these disorders. A summary of advances in research in functional neuroimaging and treatment trials is also given.

KEYWORDS

Somatoform disorders - conversion disorders - examination - diagnosis - treatment

Full Text

References

REFERENCES

1 Wessely S, Nimnuan C, Sharpe M. Functional somatic syndromes: one or many?. Lancet. 1999; 354(9182) 936-939
2 Yudofsky S C, Hales R E. Neuropsychiatry and the future of psychiatry and neurology. Am J Psychiatry. 2002; 159(8) 1261-1264
3 Task Force on DSM-IV-TR .Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR). Washington, DC; American Psychiatric Association 2000
4 Stevens H. Conversion hysteria: a neurologic emergency. Mayo Clin Proc. 1968; 43(1) 54-64
5 Cain D L. A useful eye sign in the apparently unconscious patient. Ann R Coll Surg Engl. 1983; 65(4) 265
6 Henry J A, Woodruff G HA. A diagnostic sign in states of apparent unconsciousness. Lancet. 1978; 2(8096) 920-921
7 Hoover C F. A new sign for the detection of malingering and functional paresis of the lower extremities. JAMA. 1908; 51 746-747
8 Stone J, Zeman A, Sharpe M. Functional weakness and sensory disturbance. J Neurol Neurosurg Psychiatry. 2002; 73(3) 241-245
9 Sonoo M. Abductor sign: a reliable new sign to detect unilateral non-organic paresis of the lower limb. J Neurol Neurosurg Psychiatry. 2004; 75(1) 121-125
10 Yugué I, Shiba K, Ueta T, Iwamoto Y. A new clinical evaluation for hysterical paralysis. Spine. 2004; 29(17) 1910-1913 discussion 1913
11 LaFrance Jr W C. Video NeuroImage: diagnosing conversion weakness with the Spinal Injuries Center test: when Hoover doesn't help. Neurology. 2008; 71(19) e57
12 Blocq P. Sur une affection caracteérisée par de l'astasie et de l'abasiae. Arch Neurol (Paris). 1888; 15 24-51
13 Okun M S, Rodriguez R L, Foote K D, Fernandez H H. The “chair test” to aid in the diagnosis of psychogenic gait disorders. Neurologist. 2007; 13(2) 87-91
14 Hayes M W, Graham S, Heldorf P, de Moore G, Morris J G. A video review of the diagnosis of psychogenic gait: appendix and commentary. Mov Disord. 1999; 14(6) 914-921
15 Jankovic J, Thomas M. Psychogenic tremor and shaking. In: Hallett M, Fahn S, Jankovic J, Lang AE, Cloninger CR, Yudofsky SC Psychogenic Movement Disorders: Neurology and Neuropsychiatry. Philadelphia, PA; Lippincott Williams & Wilkins and American Academy of Neurology Press 2006: 42-47
16 Schrag A. Psychogenic dystonia and reflex sympathetic dystrophy. In Hallett M, Fahn S, Jankovic J, Lang AE, Cloninger CR, Yudofsky SC Psychogenic Movement Disorders: Neurology and Neuropsychiatry. Philadelphia, PA; Lippincott Williams & Wilkins and American Academy of Neurology Press 2006: 53-61
17 LaFrance Jr W C. Psychogenic nonepileptic seizures. Curr Opin Neurol. 2008; 21(2) 195-201
18 Kunugi H, Ida I, Owashi T et al.. Assessment of the dexamethasone/CRH test as a state-dependent marker for hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a multicenter study. Neuropsychopharmacology. 2006; 31(1) 212-220
19 Simeon D, Knutelska M, Yehuda R, Putnam F, Schmeidler J, Smith L M. Hypothalamic-pituitary-adrenal axis function in dissociative disorders, post-traumatic stress disorder, and healthy volunteers. Biol Psychiatry. 2007; 61(8) 966-973
20 Pritchard III P B, Wannamaker B B, Sagel J, Daniel C M. Serum prolactin and cortisol levels in evaluation of pseudoepileptic seizures. Ann Neurol. 1985; 18(1) 87-89
21 Mehta S R, Dham S K, Lazar A I, Narayanswamy A S, Prasad G S. Prolactin and cortisol levels in seizure disorders. J Assoc Physicians India. 1994; 42(9) 709-712
22 Tunca Z, Ergene U, Fidaner H et al.. Reevaluation of serum cortisol in conversion disorder with seizure (pseudoseizure). Psychosomatics. 2000; 41(2) 152-153
23 Gerstik L, Poland R E. Chapter 6. Psychoneuroendocrinology. In: Schatzberg AF, Nemeroff CB The American Psychiatric Publishing Textbook of Psychopharmacology. Washington, DC; American Psychiatric Publishing, Inc. 2004: 115-127
24 Wyllie E The Treatment of Epilepsy: Principles and Practice. 3rd ed. Philadelphia, PA; Lippincott Williams & Wilkins 2001
25 Trimble M R. Serum prolactin in epilepsy and hysteria. BMJ. 1978; 2(6153) 1682
26 Cragar D E, Berry D T, Fakhoury T A, Cibula J E, Schmitt F A. A review of diagnostic techniques in the differential diagnosis of epileptic and nonepileptic seizures. Neuropsychol Rev. 2002; 12(1) 31-64
27 Bauer J. Epilepsy and prolactin in adults: a clinical review. Epilepsy Res. 1996; 24(1) 1-7
28 Chen D K, So Y T, Fisher R S. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology . Use of serum prolactin in diagnosing epileptic seizures: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2005; 65(5) 668-675
29 Lowe M R, de Toledo J C, Rabinstein A A, Guilla M F. Correspondence: MRI evidence of mesial temporal sclerosis in patients with psychogenic nonepileptic seizures. Neurology. 2001; 56(6) 823
30 Reuber M, Fernández G, Helmstaedter C, Qurishi A, Elger C E. Evidence of brain abnormality in patients with psychogenic nonepileptic seizures. Epilepsy Behav. 2002; 3(3) 249-254
31 Ettinger A B, Jandorf L, Cabahug C J et al.. Post-ictal SPECT in epileptic versus non-epileptic seizures. J Epilepsy. 1998; 11 67-73
32 Atmaca M, Aydin A, Tezcan E, Poyraz A K, Kara B. Volumetric investigation of brain regions in patients with conversion disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2006; 30(4) 708-713
33 Vuilleumier P, Chicherio C, Assal F, Schwartz S, Slosman D, Landis T. Functional neuroanatomical correlates of hysterical sensorimotor loss. Brain. 2001; 124(Pt 6) 1077-1090
34 Mailis-Gagnon A, Giannoylis I, Downar J et al.. Altered central somatosensory processing in chronic pain patients with “hysterical” anesthesia. Neurology. 2003; 60(9) 1501-1507
35 Ghaffar O, Staines W R, Feinstein A. Unexplained neurologic symptoms: an fMRI study of sensory conversion disorder. Neurology. 2006; 67(11) 2036-2038
36 Spence S A, Crimlisk H L, Cope H, Ron M A, Grasby P M. Discrete neurophysiological correlates in prefrontal cortex during hysterical and feigned disorder of movement. Lancet. 2000; 355(9211) 1243-1244
37 Marshall J C, Halligan P W, Fink G R, Wade D T, Frackowiak R S. The functional anatomy of a hysterical paralysis. Cognition. 1997; 64(1) B1-B8
38 Looper K J, Kirmayer L J. Behavioral medicine approaches to somatoform disorders. J Consult Clin Psychol. 2002; 70(3) 810-827
39 Kroenke K, Swindle R. Cognitive-behavioral therapy for somatization and symptom syndromes: a critical review of controlled clinical trials. Psychother Psychosom. 2000; 69(4) 205-215
40 Barsky A J, Ahern D K. Cognitive behavior therapy for hypochondriasis: a randomized controlled trial. JAMA. 2004; 291(12) 1464-1470
41 Varia I, Logue E, O'Connor C et al.. Randomized trial of sertraline in patients with unexplained chest pain of noncardiac origin. Am Heart J. 2000; 140(3) 367-372
42 Müller T, Mannel M, Murck H, Rahlfs V W. Treatment of somatoform disorders with St. John's wort: a randomized, double-blind and placebo-controlled trial. Psychosom Med. 2004; 66(4) 538-547
43 Volz H P, Möller H J, Reimann I, Stoll K D. Opipramol for the treatment of somatoform disorders results from a placebo-controlled trial. Eur Neuropsychopharmacol. 2000; 10(3) 211-217
44 Hiller W, Fichter M M, Rief W. A controlled treatment study of somatoform disorders including analysis of healthcare utilization and cost-effectiveness. J Psychosom Res. 2003; 54(4) 369-380
45 LaFrance Jr W C, Benbadis S R. Avoiding the costs of unrecognized psychological nonepileptic seizures. Neurology. 2006; 66(11) 1620-1621
46 Parker A J, Wessely S, Cleare A J. The neuroendocrinology of chronic fatigue syndrome and fibromyalgia. Psychol Med. 2001; 31(8) 1331-1345
47 Beard G M. Neurasthenia, or nervous exhaustion. Boston Medical and Surgical Journal. 1869; 3(13) 217-221
48 Chambers D, Bagnall A M, Hempel S, Forbes C. Interventions for the treatment, management and rehabilitation of patients with chronic fatigue syndrome/myalgic encephalomyelitis: an updated systematic review. J R Soc Med. 2006; 99(10) 506-520
49 Goldenberg D L, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA. 2004; 292(19) 2388-2395
50 LaFrance Jr W C. Treating patients with functional symptoms: one size does not fit all. J Psychosom Res. 2007; 63(6) 633-635
51 LaFrance Jr W C, Alper K, Babcock D for the NES Treatment Workshop participants et al. Nonepileptic seizures treatment workshop summary. Epilepsy Behav. 2006; 8(3) 451-461
52 LaFrance Jr W C, Blum A S, Miller I W, Ryan C E, Keitner G I. Methodological issues in conducting treatment trials for psychological nonepileptic seizures. J Neuropsychiatry Clin Neurosci. 2007; 19(4) 391-398
53 LaFrance Jr W C, Miller I W, Ryan C E et al.. Cognitive behavioral therapy for psychogenic nonepileptic seizures. Epilepsy Behav. 2009; 14(4) 591-596
54 LaFrance Jr W C, Blum A S, Ryan C E, Miller I W, Keitner G I. Comorbidities in patients with psychogenic nonepileptic seizures. Neurology. 2009; 72(11 suppl 3) A328

W. Curt LaFranceJr. M.D. M.P.H.

Director of Neuropsychiatry and Behavioral Neurology, Rhode Island Hospital

593 Eddy Street, Potter 3, Providence, RI 02903

Email: William_LaFrance_Jr@brown.edu